Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia invivo

Cancer Cell

Volumn 27, Issue 4, 2015, Pages 589-602

  Borkin, Dmitry ^a   He, Shihan ^a   Miao, Hongzhi ^a   Kempinska, Katarzyna ^a   Pollock, Jonathan ^a,b   Chase, Jennifer ^b   Purohit, Trupta ^a   Malik, Bhavna ^a   Zhao, Ting ^b   Wang, Jingya ^a,f   Wen, Bo ^b   Zong, Hongliang ^c   Jones, Morgan ^b   Danet Desnoyers, Gwenn ^d   Guzman, Monica L ^c   Talpaz, Moshe ^a   Bixby, Dale L ^a   Sun, Duxin ^b   Hess, Jay L ^a,e   Muntean, Andrew G ^a   Maillard, Ivan ^a,b   Cierpicki, Tomasz ^a   Grembecka, Jolanta ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e INDIANA UNIVERSITY   (United States)

^f MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHIONINE; MI 463; MI 503; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; MEN1 PROTEIN, HUMAN; MEN1 PROTEIN, MOUSE; MLL PROTEIN, HUMAN; MLL PROTEIN, MOUSE; ONCOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; GENETICS; METABOLISM; PRECLINICAL STUDY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; HEMATOPOIESIS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MICE; MICE, INBRED C57BL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED;

EID: 84928037867     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.02.016     Document Type: Article

References (34)

1. Artinger E.L., Mishra B.P., Zaffuto K.M., Li B.E., Chung E.K., Moore A.W., Chen Y., Cheng C., Ernst P. An MLL-dependent network sustains hematopoiesis. Proc. Natl. Acad. Sci. USA 2013, 110:12000-12005.
2. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
3. Caslini C., Yang Z., El-Osta M., Milne T.A., Slany R.K., Hess J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007, 67:7275-7283.
4. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
5. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
6. Dimartino J.F., Cleary M.L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br. J. Haematol. 1999, 106:614-626.
7. Ernst P., Wang J., Korsmeyer S.J. The role of MLL in hematopoiesis and leukemia. Curr. Opin. Hematol. 2002, 9:282-287.
8. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
9. Gal H., Amariglio N., Trakhtenbrot L., Jacob-Hirsh J., Margalit O., Avigdor A., Nagler A., Tavor S., Ein-Dor L., Lapidot T., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20:2147-2154.
10. Grembecka J., Belcher A.M., Hartley T., Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J.Biol. Chem. 2010, 285:40690-40698.
11. Grembecka J., He S., Shi A., Purohit T., Muntean A.G., Sorenson R.J., Showalter H.D., Murai M.J., Belcher A.M., Hartley T., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
12. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
13. He S., Senter T.J., Pollock J., Han C., Upadhyay S.K., Purohit T., Gogliotti R.D., Lindsley C.W., Cierpicki T., Stauffer S.R., Grembecka J. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J.Med. Chem. 2014, 57:1543-1556.
14. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 2004, 10:500-507.
15. Jaatinen T., Hemmoranta H., Hautaniemi S., Niemi J., Nicorici D., Laine J., Yli-Harja O., Partanen J. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 2006, 24:631-641.
16. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
17. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
18. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
19. Li B.E., Gan T., Meyerson M., Rabbitts T.H., Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 2013, 122:2039-2046.
20. Maillard I., Hess J.L. The role of menin in hematopoiesis. Adv. Exp. Med. Biol. 2009, 668:51-57.
21. Maillard I., Chen Y.X., Friedman A., Yang Y., Tubbs A.T., Shestova O., Pear W.S., Hua X. Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood 2009, 113:1661-1669.
22. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br. J. Haematol. 2011, 152:141-154.
23. McMahon K.A., Hiew S.Y., Hadjur S., Veiga-Fernandes H., Menzel U., Price A.J., Kioussis D., Williams O., Brady H.J. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007, 1:338-345.
24. Peloquin G.L., Chen Y.B., Fathi A.T. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013, 4:735-746.
25. Rodríguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
26. Shi A., Murai M.J., He S., Lund G., Hartley T., Purohit T., Reddy G., Chruszcz M., Grembecka J., Cierpicki T. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
27. Slany R.K. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 2005, 23:1-9.
28. Slany R.K. The molecular biology of mixed lineage leukemia. Haematologica 2009, 94:984-993.
29. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
30. Tomizawa D., Koh K., Sato T., Kinukawa N., Morimoto A., Isoyama K., Kosaka Y., Oda T., Oda M., Hayashi Y., et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007, 21:2258-2263.
31. Xu B., Li S.H., Zheng R., Gao S.B., Ding L.H., Yin Z.Y., Lin X., Feng Z.J., Zhang S., Wang X.M., Jin G.H. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc. Natl. Acad. Sci. USA 2013, 110:17480-17485.
32. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
33. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
34. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.